another as third-quarter versus revenues we today. joining Increased but you, for demand primarily prior portfolio. Thank due you growing quarter call our Starting to product on our had top-line our strong year, new and with double-digits as yet Giovanni, our for performance all with brands, Slide well thank demand. in-line X,
So on prior light expected up fourth that strongly sales strong XX% growth versus occurs prior year, global In by prescription driven third year. shed in with growth and gap our perform quarters usual, continues in X. liability be let and market Sequentially, total very year. to by continues some last Eliquis as of of class Slide to U.S., volumes. product sales XX% me XX% with on coverage impacted a performance, with share Demand new-to-brand year. the were the each some large starting growth the Eliquis versus versus grew sales gains
execution prescription - share strong new-to-brand XX% to overall to and to with a grow. rank prior grew Eliquis' primarily continue remain sales versus share room growth. Shares all OAC additional around in continue due the expect total Eliquis' further translate class. to within number year growing to to to increase key as the really We Internationally, to one expect multiple pleased growth and with across geographies world We demand. markets grow continues
Slide XX. moving Now performance Opdivo to on
the And had for X%, cancer the our sales the primarily uptake brand, first-line versus in other work We are inventory million demand sales prior by new sequentially, growth of year. of and launches In X% U.S. with we second X% offset versus build XX in pleased growth down the noted driven lung last year. by quarter. in we momentum with grew this year, was a which continued multiple
We've newer to quarter Outside indications U.S. last access versus by primarily as year. with XX% in we positions was expanded Turkey teams sales Growth Latin pleased and with execute America, strong in another strong had commercial continued Russia. and melanoma retained driven indications. are Our very up indications the the our well. of and renal and demand such new core performance for
expansion as in high. continue launches, further other first-line now read the is Japan We key including approvals to Germany from launches growth ongoing contribute opportunities future These lung May new and that of launches expected on years, to in see of our for strong trials gastric in and next momentum markets. update our the clinical discussions 's few cancer, with launches, first-line esophageal reimbursement internationally. Opdivo as are Based to recent out current with the year, growth together pricing well cancer renal continued and positive esophageal on promise from over next we'll from potential and
to use sales and triple primarily XX, treatment therapies demand and globally, continued driven based by in portfolio was triple XX% In-Line lines. Turning increasing demand our driven global myeloma XX% on up Pomalyst by for multiple based REVLIMID earlier Slide therapies for were duration. up
quarter. we're on on $X.X generate billion us lifecycle. our pleased Now giving very products XXX This to business renewing run diversified already that XX, million we sales our which is with portfolio to Slide to way products earlier new of close continue our are confidence third rate, that great be products annualizing the moving new with in to their much our in new
the We're recommends X supports as up demand treat U.S. a instead response to to of XX% their driven million new which generated update X XX by encouraged patients, in year. recent XX This patients So the treatment primarily previously with weeks. weeks the well that refractory to very monitor ESA in sales build. potentially by in XXX let's Reblozyl, growth sooner quarter, of continued and now NCCN evaluating versus in third as was million journey. recommended need guideline at MDS $XX $XX million a the earlier inventory ESA start prior strong to the Sales
ensuring focused appropriate the Additionally, one U.S., impacted sustained in Sales received remain strong to Reblozyl the is launched. Germany. the were price year review, for launch be by on continues usual dose countries in most after benefit. Outside uptake we they where
in additional the more We to in expect reimbursement and countries for XXXX discussions, pending drive in to growth the in and Italy brand. launch QX Netherlands
of expect to to this to be revenues exceed similar months quarter our supply, sales Abecma T, cell BCMA in million million in to generate Abecma, Remember our XQ and quarter that XX versus We X.X third remains QX largely reflects having mid-May, revenues XX Demand we launched the full sales. quarter. a therapies, quarter only in of robust. for of Breyanzi. first-in-class CAR so second Demand consisted continues Moving performance the and QX.
to to Breyanzi moving pleased CDXX lymphoma to XX million quarter. ASH Now clinically B-cell sales extremely versus due in and profile. look second-line to Large at patient were XX in the earlier line forward meaningful best-in-class the Breyanzi, million PFS data patients data have to T quarter physicians our XXXX. We're this treatment increased presenting the CAR demand bringing in prior in Sales and recognizing with
Zeposia, in prescriptions. inventory build of by to The of were XX Turning in continues written launch, launch quarter multiple million driven terms the SXP one-time in Zeposia progress remains MS global the well, sclerosis the where U.S. to revenues choice and
to SXP focus in only but oral MS. the also as choice, not the choice treatment continue of establishing We Zeposia on of
growth by UC trailers launch June. is and of launch also the the Our We're encouraged well initial the new uptake since in in U.S.. in in progressing number
building And making establishing received just Europe. have as broadening volume, look this access demand also living time. medicine, biologic-like soon opinion oral possible. pleased as with to while Zeposia very on for focus in CHMP We're available patients Our to positive forward to is over UC
XX progress quarter, establishing prior the AML making patients. driven demand as increased quarter. primarily first-line of generated million sales well as by inventory maintenance and we're Onureg Lastly, and versus Onureg build in on
the focus and to continue shaping adherence. We maintenance segment new adoption patient on and increasing
quarter. through to increase prior already a let few margin year Operating due strong our covered versus key for P&L to other expenses XX. so attention non-GAAP walk the slide items. payments. Gross We've quarter you line our primarily me over lower were COVID prior MS&A -launch sales royalty recovery, due Now of let's on did turn slightly higher to investment investments than last in pre versus softness the shifted to also year, to MS&A due our and R&D particularly that fourth due supporting but experience quarter have activities. launch some timing to the in
XX.X% Rate XX% was Our Effective earnings Tax primarily mix. EPS driven Overall, year-over-year. by of increased non-GAAP
marketable Now almost moving Sheet operations and liquidity billion securities, Balance strong cash flow capital XX, from of on with the remains quarter. $XX to in in our and X.X and position billion cash a our allocation Slide strong
unchanged. allocation priorities remain capital Our
to allocation. flexibility financial a We support have significant capital balanced to approach
to renew We've paying down in business are our priorities deals through as assets. and capital portfolio bringing development a returning to to shareholders. year, diversify Company. top our Our priority development, continue a business and this Business differentiated several early-stage debt, development executed leading innovation-based remains
down paid X year-to-date, strong in to maintaining rating. investment-grade are have We committed debt and billion our
shareholders, board share and returning repurchases. dividend approval we're it committed opportunistic growing subject As to our about to capital relates remain to
We have of billion authorization remaining billion we have and already purchased our currently to-date, X X.X shares program. in approximately
on the XX, and performance lower of strong end based we in guidance. Slide non-GAAP the Now, the quarter, raising sales turning to on reaffirming our EPS our guidance full-year
XX%. be at higher to revenues We our continue to approximately the to and of end increase guidance margin gross expect
R&D guidance the year. Moving we and are for to operating MS&A our maintaining expenses,
expecting we shifted investments by in the higher As I earlier, due timing mentioned that expenses quarter. fourth MS&A quarter of are to
providing the This our back progress. updating with execute we're and around employees dedication XX.X% and had remarkable to to that, rate achieved approximately our turn primarily our against passion of earnings it to our tax you quarter been over well will the world, and and I'm I due renew look Giovanni to another I performance. plans Company, our our not performance now Q&A. All-in-all, portfolio. Additionally, mix. can We on and for With future without guidance continue to diversify Tim updates for and to the forward pleased
